Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients.
Saved in:
| Title: | Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO |
|---|---|
| Authors: | Parfrey PS; Department of Medicine, Memorial University, St John's, Newfoundland, Canada., Burke SK; Akebia Therapeutics, Inc., Cambridge, MA., Chertow GM; Stanford University School of Medicine, Palo Alto, CA., Eckardt KU; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany., Jardine AG; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK., Lewis EF; Stanford University School of Medicine, Palo Alto, CA., Luo W; Akebia Therapeutics, Inc., Cambridge, MA., Matsushita K; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., McCullough PA; Cardiorenal Society of America, Phoenix, AZ., Minga T; Akebia Therapeutics, Inc., Cambridge, MA., Winkelmayer WC; Section of Nephrology, Baylor College of Medicine, Houston, TX. |
| Source: | Kidney medicine [Kidney Med] 2023 May 12; Vol. 5 (7), pp. 100667. Date of Electronic Publication: 2023 May 12 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101756300 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0595 (Electronic) Linking ISSN: 25900595 NLM ISO Abbreviation: Kidney Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
